Considering that IREB2 was experimentally found to affect the expression of the TLR4/NF-κB pathway, we speculate that IREB2 inhibits NAFLD progression by regulating the TLR4/NF-κB pathway. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.